

case study

First Global Enrollment & Center of Excellence in a Rare Disease Phase IV Trial

Context

Panoramic Health was named a Center of Excellence by the sponsor and became the first global site to enroll patients in a Phase IV trial for ANCA-associated vasculitis, a rare autoimmune disease marked by inflammation of small blood vessels. Despite restrictive protocol criteria, the network successfully identified and enrolled eligible patients

Objectives

Panoramic Health sites were selected to contribute to global enrollment efforts for a Phase IV trial that aimed to evaluate the long-term safety and efficacy of a drug therapy in patients with ANCA-associated vasculitis.

- **Global enrollment goal:** 300 patients
- **Panoramic enrollment goal:** Not assigned
- **Target population:** Patients with ANCA Vasculitis

Process

Panoramic Health leveraged its network expertise, advanced EMR-driven workflows, and deep experience in rare-disease research to rapidly identify newly diagnosed patients who met the protocol's eligibility criteria. Coordinated prescreening and intake ensured swift enrollment even within this challenging population

Impact

By enrolling hard-to-reach, incident patients under restrictive criteria, Panoramic Health reinforced its reputation as a trusted partner in rare disease trials.

- **First site globally** to enroll patients
- **7 patients enrolled** across 2 Panoramic Health sites
- Recognized as a **Center of Excellence** by the sponsor